Related Experiment Video
Updated: May 17, 2026

Intracellular Refolding Assay
Published on: January 24, 2012
Heat shock proteins, autoimmunity, and cancer treatment
Stuart K Calderwood1, Mary Ann Stevenson, Ayesha Murshid
1Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA.
Abstract:
Heat shock proteins (HSPs) have been linked to the therapy of both cancer and inflammatory diseases, approaches that utilize contrasting immune properties of these proteins. It would appear that HSP family members Hsp60 and Hsp70, whether from external sources or induced locally during inflammation, can be processed by antigen-presenting cells and that HSP-derived epitopes then activate regulatory T cells and suppress inflammatory diseases. These effects also extend to the HSP-rich environments of cancer cells where elevated HSP concentrations may participate in the immunosuppressive tumor milieu. However, HSPs can also be important mediators of tumor immunity. Due to their molecular chaperone properties, some HSPs can bind tumor-specific peptides and deliver them deep into the antigen-processing pathways of antigen-presenting cells (APCs). In this context, HSP-based vaccines can activate tumor-specific immunity, trigger the proliferation and CTL capabilities of cancer-specific CD8+ T cells, and inhibit tumor growth. Further advances in HSP-based anticancer immunotherapy appear to involve improving the properties of the molecular chaperone vaccines by enhancing their antigen-binding properties and combating the immunosuppressive tumor milieu to permit programming of active CTL capable of penetrating the tumor milieu and specifically targeting tumor cells.
Insights
Heat shock proteins (HSPs) can suppress inflammation and cancer by modulating immune cells. HSP-based vaccines show promise for cancer immunotherapy by activating tumor-specific immunity.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Heat shock proteins (HSPs) play dual roles in immunity, influencing both inflammatory diseases and cancer.
- HSPs like Hsp60 and Hsp70 can be processed by antigen-presenting cells (APCs) to activate regulatory T cells, suppressing inflammation.
- In cancer, elevated HSPs can contribute to an immunosuppressive tumor microenvironment, but also mediate anti-tumor immunity.
Purpose of the Study:
- To explore the contrasting roles of heat shock proteins (HSPs) in cancer and inflammatory disease therapy.
- To elucidate the mechanisms by which HSPs influence immune responses in both disease contexts.
- To identify strategies for enhancing HSP-based cancer immunotherapy.
Main Methods:
- Analysis of HSP processing by antigen-presenting cells (APCs).
- Investigation of HSP-derived epitopes in T cell activation and immune suppression.
- Evaluation of HSP molecular chaperone properties in antigen presentation for cancer vaccines.
Main Results:
- HSPs can activate regulatory T cells, leading to suppression of inflammatory diseases.
- HSPs in the tumor microenvironment can contribute to immunosuppression but also mediate anti-tumor immunity.
- HSP-based vaccines can activate tumor-specific CD8+ T cells and inhibit tumor growth.
Conclusions:
- HSPs exhibit complex immunomodulatory functions relevant to both inflammation and cancer.
- HSP-based strategies hold potential for treating inflammatory conditions and advancing cancer immunotherapy.
- Optimizing HSP vaccines by enhancing antigen binding and overcoming tumor immunosuppression is crucial for effective cancer treatment.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Psychoneuroimmunology: Diabetes and Cancer
Tumor Immunotherapy
Other Stress Responses in Bacteria
Regulation of the Unfolded Protein Response
Cell-mediated Immune Responses

